scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

TL;DR: In this paper, the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

TL;DR: In this article , the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI

Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3.

TL;DR: In this paper, a systematic review and meta-analysis was conducted to compare the safety and efficacy of 2019 novel coronavirus disease (COVID-19) vaccines according to vaccine platform and SARS-COV-2 infection severity.
Journal ArticleDOI

OUP accepted manuscript

TL;DR: In this article , the authors compared 2-dose vaccine effectiveness by vaccine type (mRNA and/or ChAdOx1), interval between doses, and time since second dose in 2 of Canada's larger provinces.
Journal ArticleDOI

Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups

TL;DR: In this paper , the authors used GP electronic health record data, sentinel virology swabbing and antibody testing within a cohort of 712 general practices across England to estimate vaccine antibody response and vaccine effectiveness against medically attended COVID-19 amongst individuals in clinical risk groups using cohort and test-negative case control designs.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -